Regular review: Ulcerative colitis

British Medical Journal

Volumn 320, Issue 7242, 2000, Pages 1119-1123

  Ghosh, Subrata ^a   Shand, Alan ^a   Ferguson, Anne ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; MESALAZINE;

ARTICLE; BARIUM ENEMA; COLON RESECTION; COLONOSCOPY; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; HUMAN; ILEOANAL ANASTOMOSIS; ONSET AGE; PRIORITY JOURNAL; PROCTOCOLECTOMY; SIGMOIDOSCOPY; ULCERATIVE COLITIS; CHRONIC DISEASE; COLON TUMOR; METHODOLOGY; RECURRENT DISEASE; REVIEW; SCLEROSING CHOLANGITIS; TREATMENT FAILURE;

CHOLANGITIS, SCLEROSING; CHRONIC DISEASE; COLITIS, ULCERATIVE; COLONIC NEOPLASMS; DIAGNOSIS, DIFFERENTIAL; HUMANS; PROCTOCOLECTOMY, RESTORATIVE; RECURRENCE; TREATMENT FAILURE;

EID: 0034701402     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.320.7242.1119     Document Type: Article

References (51)

1. 1 Probert CS, Javanthi V, Pinder D, Wicks AC, Mayberry JF. Epidemiological study of ulcerative proctocolitis in Indian migrants and the indigenous population of Leicestershire. Gut 1992;33:687-93.
2. 2 Hendriksen C, Kreiner S, Binder V. Long term prognosis in ulcerative colitis based on results from a regional group from the county of Copenhagen. Gut 1985;26:158-63.
3. 3 Allan RN, Rhodes JM, Hanauer SB, Keighley MRB, Alexander-Williams J, Fazio VW. Inflammatory bowel disease, 3rd ed. Edinburgh: Churchill Livingstone, 1997.
4. 4 Targan SR, Shanahan F. Inflammatory bowel disease: from bench to bedside. Maryland: Williams and Wilkins, 1994.
5. 5 Korelitz BI, Sohn N. Management of inflammatory bowel disease. St Louis, MI: Mosby Year Book, 1992.
6. 6 British Society of Gastroenterology. Guidelines in gastroenterology 4. Inflammatory bowel disease. BSG, 1996.
7. 7 Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults. Am J Gastroenterol 1997;92:204-11.
8. 8 Machida HM, Catto Smith AG, Gall DG, Trevenen C, Scott RB. Allergic colitis in infancy: clinical and pathologic aspects. J Pediatr Gastroenterol Nutr 1994;19:22-6.
9. 9 Pullan RD, Thomas GA, Rhodes M, Newcombe RG, Williams GT, Allen A, et al. Thickness of adherent mucus gel on colonic mucosa in humans and its relevance to colitis. Gut 1994;35:353-9.
10. 10 Tysk C, Riedesel H, Lindberg E, Panzini B, Podolsky D. Colonic glycoproteins in monozygotic twins with inflammatory bowel disease. Gastroenterology 1991;100:419-23.
11. 11 Tsai HH, Dwarakanath AD, Hart CA. Increased faecal mucin sulphatase activity in ulcerative colitis: a potential target for treatment. Gut 1995;36:570-6.
12. 12 Rutgeerts P, D'Hans G, Hiele M, Geboes K, Vantrappen G. Appendectomy protects against ulcerative colitis. Gastroenterology 1994;106:1251-3.
13. 13 Dijkstra, B, Bagshaw PF, Frizelle FA. Appendectomy protects against ulcerative colitis even when controlling for cigarette smoking. Dis Colon Rectum 1999;12:334-6.
14. 14 Pitcher MCL, Cummings JH. Hydrogen sulphide - a bacterial toxin in ulcerative colitis. Gut 1996;39:1-4.
15. 15 Das KM, Dasgupta A, Mandal A, Geng X. Autoimmunity to cytoskeletal protein tropomyosin. A clue to the pathogenetic mechanisms for ulcerative colitis. J Immunol 1993;150:2487-93.
16. 16 Cantrell M, Prindiville T, Gershwin ME. Autoantibodies to colonic cells and subcellular fractions in inflammatory bowel disease: do they exist? J Autoimmun 1990;3:307-20.
17. 17 Mosman TR, Sad S. The expanding universe of T-cell subsets - Th1, Th2 and more. Immunol Today 1996;17:38-46.
18. 18 Iruelove SC, Witts LJ. Cortisone in ulcerative colitis. Final reports on a controlled trial. BMJ 1955;ii:1041-8.
19. 19 Powell-Tuck J, Bown RL, Lennard-Jones JE. A comparison of oral prednisolone given as a single or multiple daily doses for active proctocolitis. Scand J Gastroenterol 1978;13:833-7.
20. 20 Best WR, Becktel JM, Singleton JW, Kern F. Development of a Crohn's disease activity index: national cooperative Crohn's disease study. Gastroenterology 1976;70:439-44.
21. 21 Acciulfi S, Ghosh S, Ferguson A. Strengths and limitations of the Crohn's disease activity index, revealed by an objective gut lavage test of gastro-intestinal protein loss. Aliment Pharmacol Ther 1996;10:321-6.
22. 22 Hanauer SB. Balsalazide led to greater remission rates and tolerance than mesalamine in acute ulcerative colitis. Gut 1999;44:455.
23. 23 Marshall JK, Irvine EJ. Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis. Gut 1997;40:775-81.
24. 24 Somerville KW, Langman MJ, Kane SP, MacGilchrist AJ, Watkinson G, Salmon P. Effect of treatment on symptoms and quality of life in patients with ulcerative colitis: comparative trial of hydrocortisone acetate foam and prednisolone 21 phosphate enemas. BMJ 1985;291:866.
25. 25 Gionchetti P, Ardizzone S, Benvenuti ME, Bianchi Porro G, Biasco G, Cesari P, et al. A new mesalazine gel enema in the treatment of left-sided ulcerative colitis: a randomised controlled multicentre trial. Aliment Pharmacol Ther 1999;13:381-8.
26. 26 Schreiber S, Howaldt S, Schnoor M, Nikolaus S, Bauditz, Gasche C, et al. Recombinant erythropoietin for the treatment of anaemia in inflammatory bowel disease. N Engl J Med 1996;334:619-23.
27. 27 Nilsson A, Danielsson A, Lofberg R, Benno P, Bergman L, Fausa O, et al. Olsalazine versus sulphasalazine for relapse prevention in ulcerative colitis: a multicenter study. Am J Gastroenterol 1995;90:381-7.
28. 28 Courtney MG, Nunes DP, Bergin CF, O'Driscoll M, Trimble V, Keeling PW, et al. Randomised comparison of olsalazine and mesalazine in prevention of relapses in ulcerative colitis [see comments]. Lancet 1992;339:1279-81.
29. 29 Thuluvath PJ, Ninkovic M, Calam J, Anderson M. Mesalazine induced interstitial nephritis. Gut 1994;35:1493-6.
30. 30 Stack WA, Williams D, Stevenson M, Logan RF. Immunosuppressive therapy for ulcerative colitis: results of a nationwide survey among consultant physician members of the British Society of Gastroenterologists. Aliment Pharmacol Ther 1999;13:569-75.
31. 31 Evans RC, Shim-Wong V, Morris AI, Rhodes JM. Treatment of corticosteroid resistant ulcerative colitis with heparin - a report of 16 cases. Aliment Pharmacol Ther 1997;11:1037-40.
32. 32 Gaffney PR, Doyle CT, Gaffney A, Hogan J, Hayes DP, Annis P. Paradoxical response to heparin in 10 patients with ulcerative colitis. Am J Gastroenterol 1995;90:220-3.
33. 33 Lichtiger S, Present DH, Kornbluth A, Gelernt I, Bauer J, Galler G, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994;330:1841-5.
34. 34 Treem WR, Davis PM, Justinich CJ, Hyams JS. Cyclosporine for the treatment of fulminant ulcerative colitis in children: immediate response, long-term results, and impact on surgery. Dis Colon Rectum 1995;38:474-9.
35. 35 Stack WA, Long RG, Hawkey CJ. Short-and long-term outcome of patients treated with cyclosporin for severe acute ulcerative colitis. Aliment Pharmacol Ther 1998;12:973-8.
36. 36 Cohen RD, Brodsky AL, Hanauer SB. A comparison of the quality of life in patients with severe ulcerative colitis after total colectomy versus medical treatment with intravenous cyclosporin. Inflamm Bowel Dis 1999;5:1-10.
37. 37 Kelly KA. Anal sphincter saving operations for chronic ulcerative colitis. Am J Surg 1992;163:5-11.
38. 38 Seidel SA, Peach SE, Newman M, Sharp KW. Ileoanal pouch procedures: clinical outcomes and quality of life assessment. Am Surg 1999;65:40-6.
39. 39 Luukkonen P, Jarvinen H, Tanskanen M, Kahri A. Pouchitis - recurrence of the inflammatory bowel disease? Gut 1994;35:243-6.
40. 40 Mignon M, Settler C, Phillips SF. Pouchitis - a poorly understood entity. Dis Colon Rectum 1995;38:100-3.
41. 41 Stahlberg D, Gullberg K, Liljeqvist L, Hellers G, Lofberg R. Pouchitis following pelvic pouch operation for ulcerative colitis. Incidence, cumulative risk and risk factors. Dis Colon Rectum 1996;39:1012-8.
42. 42 Olsen KA, Joelsson M, Laurberg S, Oresland T. Fertility after ileal pouch-anal anastomosis in women with ulcerative colitis. Br J Surg 1999;86:493-5.
43. 43 Brentnall TA, Haggitt RC, Rabinovitch PS, Kimmey MB, Bronner MP, Levine DS, et al. Risk and natural history of colonic neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis. Gastroenterology 1996;110:331-8.
44. 44 Lashner BA, Shapiro BD, Husain A, Goldblum JR. Evaluation of the usefulness of testing for p53 mutations in colorectal cancer suveillance for ulcerative colitis. Am J Gastroenterol 1999;94:456-62.
45. 45 Holzmann K, Klump B, Borchard F, Hsieh CJ, Kuhn A, Gaco V, et al. Comparative analysis of histology, DNA content, p53 and Ki-ras mutations in colectomy specimens with long-standing ulcerative colitis. Int J Cancer 1998;76:1-6.
46. 46 Olsson R, Danielsson A, Jarnerot G, Lindstrom E, Loof L, Rolny P, et al. Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis. Gastroenterology 1991;100:1319-23.
47. 47 Roozendaal C, Van Milligen de Wit AW, Haagsma EB, Horst G, Schwarze C, Peter HH, et al. Antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis: defined specificities may be associated with distinct clinical features. Am J Gastroenterol 1998;105:393-9.
48. 48 Mitchell SA, Chapman RWG. Review article: the management of primary sclerosing cholangitis. Aliment Pharmacol Ther 1997;11:33-13.
49. 49 Lee JG, Schutz SM, England RE, Leung JW, Cotton PB. Endoscopic therapy of sclerosing cholangitis. Hepatogy 1995;21:661-7.
50. 50 Narvin S, Roberts JP, Emond JC, Lake J, Ascher NL. Liver transplantation for sclerosing cholangitis. Hepatology 1995;22:451-7.
51. 51 Loftus EV Jr, Aguilar HI, Sandborn WJ, Tremaine WJ, Krom RA, Zinsmeister AR, et al. Risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis following orthotopic liver transplantation. Hepatology 1998;27:685-90.